Breaking News Instant updates and real-time market news.

REGN

Regeneron

$376.40

5.44 (1.47%)

, SNY

Sanofi

$44.17

-0.62 (-1.38%)

15:28
04/21/17
04/21
15:28
04/21/17
15:28

EMA's CHMP issues positive opinion on Kevzara in rheumatoid arthritis

The Committee for Medicinal Products for Human Use, or CHMP, of the EMA announced it has adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kevzara, intended for the treatment of rheumatoid arthritis.

REGN

Regeneron

$376.40

5.44 (1.47%)

SNY

Sanofi

$44.17

-0.62 (-1.38%)

  • 24

    Apr

  • 03

    May

REGN Regeneron
$376.40

5.44 (1.47%)

03/29/17
SBSH
03/29/17
NO CHANGE
Target $420
SBSH
Buy
Citi sees upside to consensus expectations for Dupixent launch
Citi analyst Robyn Karnauskas believes Regeneron Pharmaceuticals is taking a smart approach to the Dupixent launch by going after the sickest moderate to severe atopic dermatitis patients. A lack of payer pushback, which is the biggest investor concern, could make the launch look better than the street expectations of $138M for 2017, Karnauskas tells investors in a research note. She keeps a Buy rating on Regeneron with a $420 price target.
03/29/17
FBCO
03/29/17
NO CHANGE
Target $485
FBCO
Outperform
Credit Suisse sees upside to Regeneron Dupixent if favorable payer environment
After FDA approved Regeneron (REGN) and Sanofi's (SNY) Dupixent, Credit Suisse analyst Alethia Young says that the pricing was higher than her expectations, but thinks that the peak opportunity is roughly around the same, remaining unchanged at $4.7B in 2025. Additionally, the analyst thinks that Regeneron/Sanofi upfront effort with payers may help early days of launch. She reiterates an Outperform rating and $485 price target on Regeneron's shares.
03/29/17
UBSW
03/29/17
NO CHANGE
Target $446
UBSW
Buy
Regeneron target raised to $446 on higher than expected Dupixent pricing at UBS
UBS analyst Carter Gould noted that on the call related to Dupixent's approval for atopic dermatitis Regeneron (REGN) and Sanofi (SNY) said that the drug's annual $37K gross price was expected to translate into a net price in the "low $30K range" annually, which is above his prior estimate near $24K. Along with raising his annual net pricing assumption, Gould increased his peak sales estimate for Dupixent in atopic dermatitis to $3.1B from $2.8B and raised his price target on Regeneron to $446 from $435 while keeping a Buy rating on the stock.
03/30/17
WEDB
03/30/17
NO CHANGE
Target $33
WEDB
Outperform
AnaptysBio price target raised to $33 from $28 at Wedbush
Wedbush analyst David Nierengarten raised his price target for AnaptysBio (ANAB) to $33 from $28 saying that Regeneron (REGN) and Sanofi's (SNY) Dupixent price suggests that higher pricing for the former's ANB020 could be achievable. The analyst reiterates an Outperform rating on AnaptysBio's shares.
SNY Sanofi
$44.17

-0.62 (-1.38%)

04/07/17
04/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lamb Weston (LW) downgraded to Hold from Buy at Stifel with analyst Christopher Growe citing the 44% up move in shares since he launched coverage in November 2016. 2. AstraZeneca (AZN), Novo Nordisk (NVO), Sanofi (SNY), Roche (RHHBY), and Grifols (GRFS) were downgraded to Reduce from Hold at HSBC. 3. AECOM (ACM) downgraded to Neutral from Outperform at Baird with analyst Andrew Wittmann saying the company filed an amendment to its credit agreement suggesting likely risk to 2017 earnings, as the filing implies the company would have breached its leverage covenant without an amendment. The analyst is also cautious given the relative obscurity of the filing. Wittmann lowered his price target to $40 from $45 on AECOM shares. 4. Arista Networks (ANET) downgraded to Neutral on valuation at Nomura with analyst Jeffrey Kvaal citing valuation. 5. Maximus (MMS) downgraded to Hold from Buy at Canaccord analyst Richard Close citing expectations of a slow near-term RFP and contract award environment given the recent Trump administration transition. click here.
04/07/17
RAJA
04/07/17
NO CHANGE
RAJA
Strong Buy
Flexion CMO hiring adds to Raymond James' skepticism of takeover speculation
Raymond James analyst Elliot Wilbur previously said he was skeptical of media-driven speculation that Sanofi (SNY) was preparing to bid for Flexion (FLXN), but he views the appointment of Yamo Deniz, another former Sanofi executive, as Flexion's chief medical officer as one more reason to doubt the rumor. Deniz "joins a growing roster of hires" from Sanofi and Wilbur does not believe these individuals, who "would have the best firsthand knowledge of exactly what the buzz is on Zilretta from the Sanofi perspective," would join Flexion simply to rejoin Sanofi again. While he thinks "some deflation" of the takeout premium in the stock could follow this hiring, Wilbur keeps a Strong Buy rating on Flexion shares.
04/11/17
JPMS
04/11/17
UPGRADE
JPMS
Neutral
Sanofi upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Richard Vosser upgraded Sanofi to Neutral saying he no longer sees downside to consensus estimates. The pressure on the diabetes business now seems largely reflected in estimates, Vosser tells investors in a research note. The analyst raised his price target for the shares to EUR 87 from EUR 71.
04/11/17
04/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Conviction Buy from Buy at Goldman with analyst Drew Borst saying that the success of "Beauty and the Beast" has increased his confidence in his forecast that FY18 EPS growth will accelerate given the company's promising film slate and its read-through to consumer products. He also sees accelerating profit growth at ESPN given normalizing NBA costs and predicts record results for the Theme Parks segment. Borst keeps a $138 price target on Disney shares. 2. McDonald's (MCD) upgraded to Buy from Neutral at Cleveland Research. 3. Yelp (YELP) upgraded to Overweight from Sector Weight at Pacific Crest with analyst Brad Erickson saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG, GOOGL) and Facebook (FB). 4. Toll Brothers (TOL) upgraded to Outperform from Sector Perform at RBC Capital with analyst Robert Wetenhall citing "solid demand,strong execution, proven management, a strong luxury housing business, and consistent earnings." 5. Sanofi (SNY) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he no longer sees downside to consensus estimates. The pressure on the diabetes business now seems largely reflected in estimates, Vosser tells investors in a research note. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

LNDC

Landec

$12.55

0.6 (5.02%)

16:10
09/26/17
09/26
16:10
09/26/17
16:10
Earnings
Landec sees Q2 EPS 6c-8c, consensus 10c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

WLKP

Westlake Chemical Partners

$24.00

0.05 (0.21%)

16:10
09/26/17
09/26
16:10
09/26/17
16:10
Syndicate
Westlake Chemical Partners files to sell 4.5M units for limited partners »

UBS Investment Bank,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLKP

Westlake Chemical Partners

$24.00

0.05 (0.21%)

16:09
09/26/17
09/26
16:09
09/26/17
16:09
Hot Stocks
Westlake Chemical Partners to acquire extra 5% interest in OpCo »

Westlake Chemical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNDC

Landec

$12.55

0.6 (5.02%)

16:08
09/26/17
09/26
16:08
09/26/17
16:08
Earnings
Landec reports Q1 EPS 8c, consensus 6c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MU

Micron

$34.18

-0.69 (-1.98%)

16:08
09/26/17
09/26
16:08
09/26/17
16:08
Technical Analysis
Technical View: Micron spikes higher after earnings beat »

In the extended session…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MU

Micron

$34.18

-0.69 (-1.98%)

16:07
09/26/17
09/26
16:07
09/26/17
16:07
Hot Stocks
Micron CEO expects healthy industry fundamentals to continue into 2018 »

"Micron delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMSC

AMSC

$4.03

0.01 (0.25%)

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
AMSC completes acquisition of Infinia Technology »

AMSC announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
Micron says Q4 margin increase due to DRAM products »

Revenues for the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GFF

Griffon

$21.55

0.55 (2.62%)

, EMR

Emerson

$63.13

-0.48 (-0.75%)

16:06
09/26/17
09/26
16:06
09/26/17
16:06
Hot Stocks
Griffon amends ClosetMaid purchase agreement »

Griffon Corporation (GFF)…

GFF

Griffon

$21.55

0.55 (2.62%)

EMR

Emerson

$63.13

-0.48 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AVGR

Avinger

$0.21

-0.0211 (-9.13%)

16:04
09/26/17
09/26
16:04
09/26/17
16:04
Hot Stocks
Avinger receives CE Marking approval for in-stent restenosis treatment »

Avinger announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLBD

Blue Bird

$18.85

0.2 (1.07%)

16:03
09/26/17
09/26
16:03
09/26/17
16:03
Hot Stocks
Blue Bird enters stock repurchase agreement with Coliseum Capital »

Blue Bird Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

AMGN

Amgen

$185.60

-0.69 (-0.37%)

, SCR

Simcere

16:03
09/26/17
09/26
16:03
09/26/17
16:03
Hot Stocks
Amgen and Simcere execute agreement to co-develop four biosimilars in China »

Amgen (AMGN) and Simcere…

AMGN

Amgen

$185.60

-0.69 (-0.37%)

SCR

Simcere

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

ITCI

Intra-Cellular

16:02
09/26/17
09/26
16:02
09/26/17
16:02
Syndicate
Intra-Cellular files to sell $150M in common stock »

J. P. Morgan Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MU

Micron

16:01
09/26/17
09/26
16:01
09/26/17
16:01
Earnings
Micron reports Q4 EPS $2.02 , consensus $1.84 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SIEGY

Siemens

$68.96

-0.81 (-1.16%)

, ALSMY

Alstom

$3.91

-0.045 (-1.14%)

15:58
09/26/17
09/26
15:58
09/26/17
15:58
Hot Stocks
Siemens, Alstom confirm agreement to combine mobility businesses »

Siemens (SIEGY) and…

SIEGY

Siemens

$68.96

-0.81 (-1.16%)

ALSMY

Alstom

$3.91

-0.045 (-1.14%)

GE

General Electric

$24.97

-0.145 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

HII

Huntington Ingalls

$222.73

2.25 (1.02%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Hot Stocks
Huntington Ingalls partners with Ivis to develop compliance software »

Huntington Ingalls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$40.93

-1.44 (-3.40%)

15:50
09/26/17
09/26
15:50
09/26/17
15:50
Options
JD options volume is 2.5X daily average and calls outpace puts 4:1 »

JD options volume is 2.5X…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$171.00

-8 (-4.47%)

, INTC

Intel

$37.16

-0.02 (-0.05%)

15:42
09/26/17
09/26
15:42
09/26/17
15:42
Periodicals
Breaking Periodicals news story on Nvidia, Intel, Tesla »

Tesla shifting from…

NVDA

Nvidia

$171.00

-8 (-4.47%)

INTC

Intel

$37.16

-0.02 (-0.05%)

TSLA

Tesla

$344.99

-6.1 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 05

    Oct

  • 08

    Oct

  • 22

    Oct

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

, TWLO

Twilio

$28.86

-0.615 (-2.09%)

15:38
09/26/17
09/26
15:38
09/26/17
15:38
Hot Stocks
Amazon discussses launch of AWS Global SMS two-way text messaging »

Amazon's (AMZN)…

AMZN

Amazon.com

$939.79

-15.31 (-1.60%)

TWLO

Twilio

$28.86

-0.615 (-2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

LNDC

Landec

$11.95

-0.3 (-2.45%)

15:34
09/26/17
09/26
15:34
09/26/17
15:34
Options
Landec options imply 12.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

T

AT&T

$38.80

-0.32 (-0.82%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Periodicals
AT&T's DirecTV to allow 'some' refunds after anthem strife, WSJ says »

Certain subscribers to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Nov

AMJ

American Medical Laboratories Inc

$28.50

0.01 (0.04%)

15:30
09/26/17
09/26
15:30
09/26/17
15:30
Options
Alerian MLP attracts a bullish option play »

Alerian MLP attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.47

-1.105 (-1.28%)

15:27
09/26/17
09/26
15:27
09/26/17
15:27
Hot Stocks
AbbVie says will take one single digit price increase for 2018 »

AbbVie issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 08

    Nov

STZ

Constellation Brands, also tag STZ.B

$200.37

-0.24 (-0.12%)

15:25
09/26/17
09/26
15:25
09/26/17
15:25
Options
Constellation Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

$NSD

NASDAQ Market Internals

15:17
09/26/17
09/26
15:17
09/26/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.